Single-Center, Open-Label Study Study to Evaluate Improvement of Hair Appearance With Novel Hair Growth Serum

April 2025 | Volume 24 | Issue 4 | 8606 | Copyright © April 2025


Published online March 12, 2025

doi:10.36849/JDD.8606 

Suleima Arruda MDa, Alyssa Swearingen MDa, Zahyaa Elmadany a, Anna Nakagama BSa, Emely Alvarado Lemoine BSa, Sophia Clara Valmeus BSa, Neil Sadick MDa,b

aSadick Dermatology and Sadick Research Group; New York, NY
bWeill Cornell Medical College, President of Sadick Dermatology; New York, NY

Abstract

Background: REVIVV® is a topical hair growth serum with a proprietary formula of botanicals that addresses multiple factors involved in hair loss pathophysiology. This open-label, prospective, single-center study evaluated the efficacy of REVIVV®, a topical hair growth serum, in 20 adults (10 male, 10 female) with mild to moderate hair loss over 6 months. Participants applied the serum twice daily, and assessments were conducted at baseline, 4, 12, and 24 weeks. Dermatologist evaluations and patient self-assessments of hair quality and growth were performed using a 7-point Likert scale. Results Investigator-rated improvements in hair quality and growth increased from 0.75 and 0.81 at 4 weeks to 1.73 and 1.83 at 24 weeks, respectively. Patient-reported assessments showed that 85% of participants noted improved hair quality and growth at 24 weeks, with 50% reporting great improvement. Patient satisfaction was high, with 80% of participants being moderately or greatly satisfied at 4 weeks, increasing to 95% at 24 weeks. No adverse events related to the serum were reported throughout the study. The results demonstrate that twice-daily application of REVIVV®  over 6 months is associated with increased hair growth and improved hair quality suggesting that REVIVV®  may be an effective, non-pharmacological option for individuals seeking to improve hair growth and quality.

J Drugs Dermatol. 2025;24(4): doi:10.36849/JDD.8606 

INTRODUCTION

Hair loss is a prevalent issue affecting both men and women, often leading to considerable psychological distress. The causes of hair loss are multifaceted, encompassing medical conditions, medications, emotional and physical stress, post-partum, hormonal changes, aging, damage from styling or processing, or all in combination.1,2 This process leads to an alteration in the hair cycle, with a shortening of the anagen phase, a lengthening of the latency period, and miniaturization of the hair shaft turning from terminal into vellus-like hair. Perifollicular inflammation and immune deposits have also been shown to contribute to the pathophysiology.3

Pharmacological treatments for hair loss like finasteride and minoxidil are available but have side effects and their mechanisms of action are not well understood. Vitamins, minerals, and other nutrients are frequently used in a large range of products claiming to be efficient against hair loss but data from prospective intervention studies remain scarce.4-8

REVIVV® is a topical serum supplement, containing vitamins, minerals, proteins, and nutraceutical-grade botanical bioactives designed to restore hair health. The formulation of botanicals includes potent anti-inflammatory, anti-stress adaptogenic, antioxidant, and DHT-inhibiting properties tailored to the specific needs of men and women. A previous study demonstrated that twice daily application of REVIVV over 8 weeks resulted in a statistically significant increase in hair thickness in the crown and vertex of the scalp in both males and females with androgenetic alopecia. Results also showed high patient satisfaction. Given these findings, we were interested in exploring the benefits of prolonged use of REVIVV.9

The present study aimed to evaluate the degree of change in hair growth and hair quality observed by patients and physicians after using REVIVV hair growth serum for 6 months. Patient satisfaction, safety, and tolerability were also assessed.

MATERIALS AND METHODS

Study Design

This was an open-label, prospective, single-center study in adult subjects. The study was conducted in one dermatologic office in New York City from May 2023 to March 2024 and a total of 20 evaluable subjects were enrolled. This study was conducted in accordance with the International Conference on Harmonization Harmonized Tripartite Guideline for Good Clinical Practice, the Declaration of Helsinki, and applicable national 

Close Menu